A model to predict mortality following Pseudomonas aeruginosa bacteremia

被引:24
作者
Hirsch, Elizabeth B. [1 ,2 ]
Cottreau, Jessica M. [1 ,2 ]
Chang, Kai-Tai [1 ]
Caeiro, Juan-Pablo [2 ]
Johnson, Michael L. [1 ]
Tam, Vincent H. [1 ,2 ]
机构
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] St Lukes Episcopal Hosp, Houston, TX 77030 USA
关键词
Health care-associated infection; Multidrug-resistant; Mathematical modeling; Bloodstream infection; Probability; CARE-ASSOCIATED INFECTIONS; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE BACILLI; ANTIMICROBIAL THERAPY; RISK-FACTORS; PATIENT OUTCOMES; IMPACT; RESISTANCE; MECHANISMS; SUSCEPTIBILITY;
D O I
10.1016/j.diagmicrobio.2011.09.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Infections caused by Pseudomonas aeruginosa are associated with significant mortality. Existing mathematical models identifying mortality risk factors lack validation. We developed and validated a model to predict mortality in patients with P. aeruginosa bacteremia. Risk factors for 30-day mortality were examined through multivariate logistic regression in 114 patients. Independent predictors of mortality included isolation of a multidrug-resistant strain, APACHE II >= 23 and age >= 65 years. Clonality was assessed for multidrug-resistant isolates. Predicted probability of 30-day mortality was validated in 49 patients, after conditioning the model by the identified risk factors. The patients were split into 'high-risk' and 'low-risk' groups based on model-predicted mortality; the observed/expected ratios were 1.21 and 1.92, respectively. Our model was reasonable in predicting 30-day mortality in patients with P. aeruginosa bacteremia. Our results may be useful for developing strategies to reduce mortality attributed to P. aeruginosa. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 22 条
[1]   Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms [J].
Bhat, Sunil V. ;
Peleg, Anton Y. ;
Lodise, Thomas P., Jr. ;
Shutt, Kathleen A. ;
Capitano, Blair ;
Potoski, Brian A. ;
Paterson, David L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) :4390-4395
[2]   Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa [J].
Bonomo, Robert A. ;
Szabo, Dora .
CLINICAL INFECTIOUS DISEASES, 2006, 43 :S49-S56
[3]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[4]   National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 [J].
Cardo, D ;
Horan, T ;
Andrus, M ;
Dembinski, M ;
Edwards, J ;
Peavy, G ;
Tolson, J ;
Wagner, D .
AMERICAN JOURNAL OF INFECTION CONTROL, 2004, 32 (08) :470-485
[5]   Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia [J].
Chamot, E ;
El Amari, EB ;
Rohner, P ;
Van Delden, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) :2756-2764
[6]   Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer -: Retrospective analysis of 245 episodes [J].
Chatzinikolaou, I ;
Abi-Said, D ;
Bodey, GP ;
Rolston, KVI ;
Tarrand, JJ ;
Samonis, G .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :501-509
[7]   Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin [J].
DeFife, Robyn ;
Scheetz, Marc H. ;
Feinglass, Joe M. ;
Postelnick, Michael J. ;
Scarsi, Kimberly K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1074-1079
[8]   Overview of nosocomial infections caused by gram-negative bacilli [J].
Gaynes, R ;
Edwards, JR .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) :848-854
[9]  
Hirsch EB, 2010, EXPERT REV PHARM OUT, V10, P441, DOI [10.1586/erp.10.49, 10.1586/ERP.10.49]
[10]   Pseudomonas aeruginosa bacteremia:: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome [J].
Kang, CI ;
Kim, SH ;
Kim, HB ;
Park, SW ;
Choe, YJ ;
Oh, MD ;
Kim, EC ;
Choe, KW .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) :745-751